These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 15000423)

  • 1. Optimization of individual and population designs using Splus.
    Retout S; Mentré F
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):417-43. PubMed ID: 15000423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models.
    Dumont C; Lestini G; Le Nagard H; Mentré F; Comets E; Nguyen TT;
    Comput Methods Programs Biomed; 2018 Mar; 156():217-229. PubMed ID: 29428073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.
    Dumont C; Mentré F; Gaynor C; Brendel K; Gesson C; Chenel M
    Clin Pharmacokinet; 2013 Jan; 52(1):43-57. PubMed ID: 23212609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0.
    Bazzoli C; Retout S; Mentré F
    Comput Methods Programs Biomed; 2010 Apr; 98(1):55-65. PubMed ID: 19892427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of a modified Fedorov exchange algorithm to optimise sampling times for population pharmacokinetic experiments.
    Ogungbenro K; Graham G; Gueorguieva I; Aarons L
    Comput Methods Programs Biomed; 2005 Nov; 80(2):115-25. PubMed ID: 16139390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design in nonlinear mixed effects models: optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates.
    Retout S; Comets E; Samson A; Mentré F
    Stat Med; 2007 Dec; 26(28):5162-79. PubMed ID: 17486667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of population D-optimal designs via pharmacokinetic simulations.
    Hooker AC; Foracchia M; Dodds MG; Vicini P
    Ann Biomed Eng; 2003 Jan; 31(1):98-111. PubMed ID: 12572660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.
    Bertrand J; Comets E; Laffont CM; Chenel M; Mentré F
    J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):317-39. PubMed ID: 19562469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Some considerations on the design of population pharmacokinetic studies.
    Duffull S; Waterhouse T; Eccleston J
    J Pharmacokinet Pharmacodyn; 2005 Aug; 32(3-4):441-57. PubMed ID: 16284917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tutorial for $DESIGN in NONMEM: Clinical trial evaluation and optimization.
    Bauer RJ; Hooker AC; Mentre F
    CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1452-1465. PubMed ID: 34559958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis.
    Hashimoto Y; Sheiner LB
    J Pharmacokinet Biopharm; 1991 Jun; 19(3):333-53. PubMed ID: 1875286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of covariance between random effects in design for nonlinear mixed-effect models with an illustration in pediatric pharmacokinetics.
    Dumont C; Chenel M; Mentré F
    J Biopharm Stat; 2014; 24(3):471-92. PubMed ID: 24697342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fisher information matrix for nonlinear mixed effects multiple response models: evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model.
    Bazzoli C; Retout S; Mentré F
    Stat Med; 2009 Jun; 28(14):1940-56. PubMed ID: 19266541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic algorithms-based design and optimization of statistical quality-control procedures.
    Hatjimihail AT
    Clin Chem; 1993 Sep; 39(9):1972-8. PubMed ID: 8375083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of simulated annealing for finding optimal population designs.
    Duffull SB; Retout S; Mentré F
    Comput Methods Programs Biomed; 2002 Jul; 69(1):25-35. PubMed ID: 12088590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statistical evaluation of clinical trial design for a population pharmacokinetic study--a case study.
    Nakade S; Nishibori A; Okamoto H; Higuchi S
    Drug Metab Pharmacokinet; 2004 Oct; 19(5):381-9. PubMed ID: 15548850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust optimal design for the estimation of hyperparameters in population pharmacokinetics.
    Tod M; Mentré F; Merlé Y; Mallet A
    J Pharmacokinet Biopharm; 1998 Dec; 26(6):689-716. PubMed ID: 10485081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimisation of sampling windows design for population pharmacokinetic experiments.
    Ogungbenro K; Aarons L
    J Pharmacokinet Pharmacodyn; 2008 Aug; 35(4):465-82. PubMed ID: 18780163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics. A regulatory perspective.
    Sun H; Fadiran EO; Jones CD; Lesko L; Huang SM; Higgins K; Hu C; Machado S; Maldonado S; Williams R; Hossain M; Ette EI
    Clin Pharmacokinet; 1999 Jul; 37(1):41-58. PubMed ID: 10451782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.
    Retout S; Duffull S; Mentré F
    Comput Methods Programs Biomed; 2001 May; 65(2):141-51. PubMed ID: 11275334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.